摘要
目的观察卡培他滨联合奥沙利铂治疗胃癌的临床疗效及对C-MET,VEGFR2,AXL和RET靶点的作用。方法选取2015年5月至2017年5月收治的胃癌患者60例,给予卡培他滨联合奥沙利铂化学治疗(简称化疗)2个疗程。结果临床总有效率为56.67%;患者血清内C-MET,VEGFR2,AXL,RET基因突变与卡培他滨联合奥沙利铂药物治疗疗效有明显相关性(χ~2=5.000,4.398,4.739,5.001,P<0.05)。结论卡培他滨联合奥沙利铂治疗胃癌临床疗效较好,且能有效针对C-MET,VEGFR2,AXL,RET靶点进行治疗。
Objective To observe the clinical effect of capecitabine combined with oxaliplatin in the treatment of gastric cancer and its effect on C-MET,VEGFR2,AXL and RET targets. Methods Totally 60 patients with gastric cancer admitted to our hospital from May2015 to May 2017 were selected,all the patients were treated with capecitabine combined with oxaliplatin chemotherapy for 2 courses.Results The total effective rate was 56. 67%. The C-MET,VEGFR2,AXL and RET mutation in serum were significantly correlated with the efficacy of capecitabine combined with oxaliplatin（ χ^2= 5. 000,4. 398,4. 739,5. 001,P 〈 0. 05）. Conclusion Capecitabine combined with oxaliplatin in the treatment of gastric cancer has good clinical effect,and it can effectively treat gastric cancer against the C-MET,VEGFR2,AXL and RET targets.
作者
姜洪胜
孙建华
吴泉峰
黄国全
Jiang Hongsheng;Sun Jianhua;Wu Quanfeng;Huang Guoquan(Department of Gastrointestinal Surgery, The Central Hospital of Enshi Autonomous Prefecture, Enshi, Hubei, China 44530)
出处
《中国药业》
CAS
2018年第10期83-85,共3页
China Pharmaceuticals
关键词
卡培他滨
奥沙利铂
胃癌
疗效
靶向治疗
capecitabine
oxaliplatin
gastric cancer
curative effect
targeted therapy
